We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Agios Pharmaceuticals (AGIO - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agios Pharmaceuticals is a member of the Medical sector. This group includes 1022 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agios Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AGIO's full-year earnings has moved 90.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, AGIO has gained about 158.2% so far this year. At the same time, Medical stocks have gained an average of 1%. As we can see, Agios Pharmaceuticals is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Twist Bioscience (TWST - Free Report) . The stock is up 25.9% year-to-date.
Over the past three months, Twist Bioscience's consensus EPS estimate for the current year has increased 10.6%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Agios Pharmaceuticals belongs to the Medical - Products industry, a group that includes 87 individual stocks and currently sits at #123 in the Zacks Industry Rank. On average, stocks in this group have gained 15.1% this year, meaning that AGIO is performing better in terms of year-to-date returns.
On the other hand, Twist Bioscience belongs to the Medical - Biomedical and Genetics industry. This 504-stock industry is currently ranked #67. The industry has moved -6.3% year to date.
Investors interested in the Medical sector may want to keep a close eye on Agios Pharmaceuticals and Twist Bioscience as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Agios Pharmaceuticals (AGIO - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agios Pharmaceuticals is a member of the Medical sector. This group includes 1022 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agios Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AGIO's full-year earnings has moved 90.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, AGIO has gained about 158.2% so far this year. At the same time, Medical stocks have gained an average of 1%. As we can see, Agios Pharmaceuticals is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Twist Bioscience (TWST - Free Report) . The stock is up 25.9% year-to-date.
Over the past three months, Twist Bioscience's consensus EPS estimate for the current year has increased 10.6%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Agios Pharmaceuticals belongs to the Medical - Products industry, a group that includes 87 individual stocks and currently sits at #123 in the Zacks Industry Rank. On average, stocks in this group have gained 15.1% this year, meaning that AGIO is performing better in terms of year-to-date returns.
On the other hand, Twist Bioscience belongs to the Medical - Biomedical and Genetics industry. This 504-stock industry is currently ranked #67. The industry has moved -6.3% year to date.
Investors interested in the Medical sector may want to keep a close eye on Agios Pharmaceuticals and Twist Bioscience as they attempt to continue their solid performance.